Histone Deacetylase Inhibitors
- Histone Deacetylase Inhibitors
- Accession Number
- DBCAT001486 (DBCAT001790)
Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.
Drug Drug Description Vorinostat A histone deacetylase (HDAC) inhibitor used for the treatment of cutaneous manifestations in patients with progressive, persistent, or recurrent cutaneous T- cell lymphoma (CTCL) following prior systemic therapies. Belinostat A histone deacetylase (HDAC) inhibitor used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Panobinostat A non-selective histone deacetylase inhibitor used to treat multiple myeloma in combination with other antineoplastic agents. Pracinostat For the treatment of various forms of cancer. Tucidinostat Investigated for use/treatment in cancer/tumors (unspecified). Mocetinostat Mocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others. Entinostat Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic... CUDC-907 CUDC-907 has been used in trials studying the treatment of Lymphoma, Solid Tumors, BREAST CANCER, Multiple Myeloma, and NUT Midline Carcinoma, among others. CUDC-101 CUDC-101 has been used in trials studying the treatment of Cancer, Tumors, Liver Cancer, Breast Cancer, and Gastric Cancer, among others. CG-200745 Cg200745 has been used in trials studying the treatment of Solid Tumour. OBP-801 OBP-801 has been used in trials studying the treatment of Solid Tumor. Ricolinostat Ricolinostat is under investigation for the treatment of Breast Carcinoma and Metastatic Breast Cancer. R-306465 R306465 has been used in trials studying the treatment of Neoplasms. Abexinostat Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase... Givinostat Givinostat has been used in trials studying the treatment of Polycythemia Vera, Juvenile Idiopathic Arthritis, Duchenne Muscular Dystrophy (DMD), Chronic Myeloproliferative Neoplasms, and Polyarticular Course Juvenile Idiopathic Arthritis. Romidepsin A histone deacetylase (HDAC) inhibitor used to treat cutaneous T-cell lymphoma. Valproic acid An anticonvulsant used to control complex partial seizures and both simple and complex absence seizures. Bufexamac An NSAID used to treat skin conditions like atopic eczema and inflammatory dermatoses. Tefinostat Tefinostat is under investigation in clinical trial NCT02759601 (Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)). Nanatinostat Nanatinostat is under investigation in clinical trial NCT00697879 (Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours). 4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide Not Available Trichostatin A Not Available Tacedinaline Tacedinaline has been used in trials studying the treatment of Lung Cancer, Multiple Myeloma, and Pancreatic Cancer. Citarinostat Citarinostat is under investigation in clinical trial NCT02886065 (A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM). Acetyldinaline Acetyldinaline is under investigation in clinical trial NCT00005624 (CI-994 in Treating Patients With Advanced Myeloma).
- Drugs & Drug Targets